SEC Form 4/A · accession 0001213900-26-068921
Unicycive Therapeutics, Inc. · UNCY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
Sara Kenkare-Mitra
Director
Period of report
May 14, 2026
Accepted (ET)
Jun 15, 2026 · 5:24 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001766140
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1 | $0.00 | May 14, 2026 | A | 84,200 | A | — | — | Common Stock | 84,200 | 84,200 | D |
| Restricted Stock UnitsF2 | $0.00 | May 14, 2026 | A | 42,100 | A | — | — | Common Stock | 42,100 | 126,300 | D |
Explanation of responses
- F1Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. 11,694 shares vest upon grant and 2,339 vest monthly over 31 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer.
- F2Represents grant of restricted stock units (the "Annual RSU Award") payable solely in common stock of the Issuer. 17,542 shares vest upon grant and 3,508 vest monthly over 7 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer.